OSE Immunotherapeutics SA
PAR:OSE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
OSE Immunotherapeutics SA
Operating Income
OSE Immunotherapeutics SA
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Operating Income
-€35.3m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-22%
|
|
|
Valneva SE
PAR:VLA
|
Operating Income
-€81.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-15%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Operating Income
-€53.6m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-12%
|
|
|
Inventiva SA
PAR:IVA
|
Operating Income
-€141m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Operating Income
-$146.9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-12%
|
|
|
Abivax SA
PAR:ABVX
|
Operating Income
-€246.1m
|
CAGR 3-Years
-69%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-30%
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Operating Income?
Operating Income
-35.3m
EUR
Based on the financial report for Jun 30, 2025, OSE Immunotherapeutics SA's Operating Income amounts to -35.3m EUR.
What is OSE Immunotherapeutics SA's Operating Income growth rate?
Operating Income CAGR 10Y
-22%
The average annual Operating Income growth rates for OSE Immunotherapeutics SA have been -49% over the past three years , -23% over the past five years , and -22% over the past ten years .
